Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark.
Institute of Regional Health Research, University of Southern, Denmark, Odense, Denmark.
Br J Cancer. 2018 Nov;119(11):1367-1373. doi: 10.1038/s41416-018-0285-5. Epub 2018 Nov 14.
The aim of the present study was to validate the prognostic impact of CDX2 in patients with stage II colon cancer.
Two unbiased population-based cohorts representing all patients operated for stage II colon cancer in Denmark in 2002 and 2003. The CDX2 expression was evaluated by immunohistochemistry on whole tumour sections. Patients were classified into three groups, CDX2-positive, -moderate, and -negative, for comparison with the clinical data.
A total of 1157 patients were included. We found a significant relationship between loss of CDX2 expression and poor disease-free survival in both cohorts, p = 0.0267 and 0.0118, respectively. Five-year disease-free survival rates were 66%, 72% and 74% in the first cohort and 62%, 65%, and 75% in the second cohort for the negative, moderate, and positive CDX2 expression groups, respectively. Multiple Cox regression analysis performed on the combined cohorts confirmed an independent prognostic impact of CDX2 on disease-free survival, hazard ratio 1.543 (95% confidence interval 1.129-2.108), p = 0.0065.
This retrospective study provides validation regarding the prognostic impact of CDX2 in patients with stage II colon cancer. The results justify prospective validation clarifying its clinical impact.
本研究旨在验证 CDX2 在 II 期结肠癌患者中的预后影响。
两个独立的基于人群的队列，代表了 2002 年和 2003 年在丹麦接受 II 期结肠癌手术的所有患者。通过免疫组织化学方法对整个肿瘤切片进行 CDX2 表达评估。将患者分为 CDX2 阳性、中度和阴性三组，与临床数据进行比较。
共纳入 1157 例患者。我们发现两组患者中 CDX2 表达缺失与无病生存率显著相关，p 值分别为 0.0267 和 0.0118。第一组的 5 年无病生存率分别为 66%、72%和 74%，第二组分别为 62%、65%和 75%，分别为阴性、中度和阳性 CDX2 表达组。对合并队列进行的多因素 Cox 回归分析证实 CDX2 对无病生存率具有独立的预后影响，风险比为 1.543（95%置信区间为 1.129-2.108），p 值为 0.0065。
这项回顾性研究验证了 CDX2 在 II 期结肠癌患者中的预后影响。研究结果支持前瞻性验证，以明确其临床影响。
